Upstream Breakthrough: Novel Antibody Asedebart Normalizes Cortisol in Mid-Stage Cushing’s Disease Trial

CHICAGO — Danish pharmaceutical company H. Lundbeck A/S announced encouraging results from a mid-stage clinical trial of its investigational drug asedebart for treating Cushing’s disease, a rare and serious hormonal disorder. The data, presented today at ENDO 2026—the Endocrine Society’s annual meeting in Chicago—marks a significant step forward as Lundbeck expands its research and development beyond neurological disorders into rare, underserved conditions.

For patients struggling with the severe, wide-ranging health complications of chronic hormone excess, the trial offers early hope for a targeted treatment that works entirely differently than currently available therapies.

Early Trial Shows Targeted Efficacy

In the open-label Phase II trial (NCT06471829), which evaluated the safety, tolerability, and early efficacy of asedebart, researchers monitored 12 adult participants with Cushing’s disease. In an open-label trial, both the participants and the medical researchers know which treatment is being administered.

Following individualized dosage adjustments, urinary free cortisol (UFC) levels returned to normal in seven out of eight evaluable patients. UFC measures the body’s daily cortisol release and serves as the standard clinical biomarker to monitor treatment responses in Cushing’s disease, as it accurately reflects uncontrolled cortisol production over a full 24-hour window.

The intravenous formulation of the drug was generally well-received by trial participants, with no unexpected adverse effects reported. Crucially, the researchers identified no new safety concerns beyond what was anticipated based on how the drug functions in the body.

“All the adverse events we observe are very much in line with the drug’s mechanism of action,” noted Johan Luthman, Executive Vice President and Head of Research and Development at Lundbeck, in an interview with Reuters.

Cutting Off the Source: A Novel Upstream Mechanism

What sets asedebart apart from existing medical options is its unique “upstream” therapeutic approach. Asedebart is a humanized anti-ACTH monoclonal antibody—a type of laboratory-engineered protein designed to target specific molecules with high affinity.

By neutralizing circulating ACTH before it ever reaches the adrenal glands, asedebart inhibits neurohormonal signaling and decreases the downstream secretion of glucocorticoids (cortisol), mineralocorticoids, and androgens. This antibody-based mechanism represents a potential first-in-class treatment pathway for the disease.

The Severe Impact of Cushing’s Disease

Cushing’s disease develops when a benign (non-cancerous) tumor in the pituitary gland secretes excessive amounts of ACTH, which in turn triggers the adrenal glands to overproduce cortisol. While cortisol is commonly known as the “stress hormone” and is essential for regulating metabolism, immune function, and blood pressure, a chronic overload of it causes systematic damage to the human body.

The condition is notably rare, affecting approximately 10 to 15 people per million annually worldwide. It is most commonly diagnosed in individuals between the ages of 20 and 50, and occurs more frequently in women.

When left uncontrolled, Cushing’s disease causes severe health disruptions, including:

• Rapid upper-body weight gain and fat deposits (often around the face and upper back)

• Severe muscle weakness and fragile skin

• Cardiovascular complications, including chronic high blood pressure and type 2 diabetes

• Accelerated bone loss (osteoporosis) and a severely compromised immune system

Because of these widespread systemic complications, the condition carries a high rate of illness and an increased risk of mortality when suboptimally managed.

The Modern Treatment Landscape

For decades, surgical removal of the pituitary tumor via transsphenoidal surgery has remained the primary first-line treatment. When performed by highly experienced neurosurgeons, surgery can achieve an endocrine remission rate of up to 90% for microadenomas (very small tumors).

However, surgery is not always fully successful, tumors can recur, and some patients are poor candidates for an invasive procedure. For these individuals, long-term medical therapy becomes a necessity.

Existing medical therapies fall into three major categories:

• Steroidogenesis inhibitors: Medications like osilodrostat, ketoconazole, and metyrapone that block cortisol synthesis. These typically offer the fastest onset of action when rapid cortisol reduction is clinically vital.

• Pituitary-directed agents: Drugs such as pasireotide and cabergoline that suppress ACTH secretion at the tumor level.

• Glucocorticoid receptor antagonists: Therapies like mifepristone that don’t lower cortisol levels but instead block its effects at the cellular receptor level.

The treatment ecosystem continues to evolve. For example, the U.S. Food and Drug Administration (FDA) expanded the indication for the steroidogenesis inhibitor osilodrostat (Isturisa) to treat endogenous hypercortisolemia in adults with Cushing’s syndrome, providing an essential second-line alternative. In clinical trials like the LINC 4 Phase III study, osilodrostat demonstrated substantial efficacy, with 77% of patients achieving normalized UFC levels compared to just 8% in the placebo group.

Despite these options, clinical management remains highly complex. A consensus workshop held by the Pituitary Society—bringing together more than 50 academic researchers and clinical experts—emphasized that because individual patient responses vary wildly, accurate diagnosis and highly personalized treatment selection are critical for optimizing long-term outcomes.

Expert Perspectives and Context

While many clinical endocrinologists have welcomed the expansion of existing tools, they also emphasize the need for genuinely new therapeutic targets. The introduction of an antibody-based approach like asedebart represents a meaningful departure from managing the disease through broad chemical synthesis blockers or tumor-shrinking agents.

Medical management guidelines underscore that nearly 40% of patients with Cushing’s disease possess pituitary tumors so small that standard magnetic resonance imaging (MRI) scans fail to detect them. This lack of visibility complicates both surgical planning and targeted tumor therapy. An antibody that targets the hormone directly in circulation bypassed the need to interact directly with an elusive tumor site.

For severe, acute cases of hypercortisolism that fail to respond to optimized medical therapies, clinicians are sometimes forced to resort to a bilateral adrenalectomy (the surgical removal of both adrenal glands). While this instantly halts cortisol production, it forces the patient into lifelong adrenal insufficiency, requiring permanent hormone replacement therapy. Having a highly effective, upstream option like asedebart could potentially help some patients avoid this permanent surgical alternative.

Key Limitations and the Path Ahead

While the Phase II data presented at ENDO 2026 generated noticeable interest among the over 7,000 attendees, independent experts urge responsible caution. The trial’s exceptionally small size—just 12 participants—is a significant limitation. Early-stage, open-label trials frequently show strong, promising signals that fail to replicate when tested in larger, randomized, and placebo-controlled patient populations.

Furthermore, the trial enrolled participants primarily across clinical facilities in Georgia, including the National Institute of Endocrinology and Tbilisi Central Hospital. This geographic concentration means the results may not automatically translate to broader, globally diverse populations with differing genetic backgrounds or varied access to supportive healthcare infrastructure. The Phase II trial began on June 19, 2024, and is slated for full data completion in September 2026, meaning researchers are still gathering definitive data.

Lundbeck is already planning its next developmental phases to address clinical practicality. The company intends to transition to a new trial cohort evaluating asedebart via subcutaneous (under-the-skin) injections. This would offer a substantially more convenient delivery method for outpatients compared to the intensive intravenous infusions used in the initial trial.

The company anticipates launching pivotal late-stage Phase III trials in the second half of 2027. Given standard trial lengths and regulatory review timelines, asedebart would likely not be available to the general public until 2029 or later, assuming it achieves successful Phase III outcomes and secures regulatory approvals. Regulatory momentum is slowly building, however; Lundbeck secured an orphan drug designation for asedebart in Japan, which provides specialized regulatory support and pathways for developing treatments for rare conditions.

This clinical push aligns with a broader pharmaceutical trend toward rare disease research. Lundbeck has indicated plans to position four novel drug candidates into Phase III trials, aiming for up to three commercial launches across its portfolio by 2030. For now, the endocrine community and patients living with Cushing’s disease will continue to watch the upcoming trial phases closely, waiting to see if this promising upstream approach holds up under rigorous, large-scale clinical testing.

Medical Disclaimer

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• https://www.reuters.com/business/healthcare-pharmaceuticals/lundbeck-drug-candidate-shows-promise-cushings-disease-trial-2026-06-14/